Northern Trust Corp Has $51.17 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Northern Trust Corp raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,015,515 shares of the biotechnology company's stock after acquiring an additional 94,128 shares during the quarter. Northern Trust Corp owned approximately 0.97% of Corcept Therapeutics worth $51,172,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CORT. Kestra Investment Management LLC purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $27,000. Canada Pension Plan Investment Board bought a new position in Corcept Therapeutics during the fourth quarter valued at approximately $40,000. National Bank of Canada FI acquired a new stake in Corcept Therapeutics in the fourth quarter valued at approximately $42,000. USA Financial Formulas bought a new stake in Corcept Therapeutics in the fourth quarter worth approximately $54,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth $58,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sean Maduck sold 18,303 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the completion of the transaction, the insider now owns 85,622 shares of the company's stock, valued at approximately $5,196,399.18. This represents a 17.61 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 236,738 shares of company stock worth $20,476,238. 20.80% of the stock is currently owned by company insiders.

Corcept Therapeutics Stock Performance

NASDAQ:CORT traded down $1.15 during mid-day trading on Friday, hitting $70.23. 953,391 shares of the company's stock traded hands, compared to its average volume of 1,123,426. The firm has a market capitalization of $7.45 billion, a price-to-earnings ratio of 55.74 and a beta of 0.22. The firm has a 50 day moving average of $66.86 and a two-hundred day moving average of $60.87. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $26.87 and a 12 month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $157.21 million during the quarter, compared to analysts' expectations of $177.93 million. During the same period in the prior year, the business earned $0.25 earnings per share. Corcept Therapeutics's revenue for the quarter was up 7.1% compared to the same quarter last year. On average, equities analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CORT shares. HC Wainwright decreased their price objective on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. StockNews.com upgraded Corcept Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 6th. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Piper Sandler boosted their target price on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a report on Thursday, April 3rd. Finally, Truist Financial set a $135.00 price target on Corcept Therapeutics in a report on Tuesday, May 6th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Corcept Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $138.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.